INTRODUCTION
In recent years, the number of active agents having low aqueous solubility increased significantly. Oral delivery of poorly water soluble drugs often results in low bioavailability since the rate-limiting step for absorption from the gastrointestinal tract is a significantly slower dissolution rate (Mitchell et al., 2003) . Among the five key physicochemical properties in the early compound screening including pka, solubility, permeability, stability and lipophilicity, poor solubility tops the list of undesirable compound properties (Singh et al., 2010) . Compounds with insufficient solubility carry a higher risk of failure during discovery and development, since it may compromise other properties of compound and add undesirable properties, can influence both pharmacokinetic and pharmacodynamic properties of the compound and finally may affect the bioavailability (Alsenz and Kansy, 2007; Sharma et al., 2013) . Thus, many molecules that are biologically active in vitro are inactive in vivo as a result of their limited solubility and slow rate of dissolution (Ficarra et al., 2000; Zingone and Rubessa, 2005) . So, formulation approaches are being improved to enhance bioavailability of poorly water-soluble drugs. One such approach to significantly enhance dissolution of such drugs is to prepare solid lipid nanoparticles. SLNs are sub-micron size colloidal carriers ranging from 50 to 1000 nm, which are composed of physiological lipid, have been dispersed in water or in aqueous surfactant solution. SLNs possess solid lipid core matrix and solubilize lipophilic molecules (Waghmare et al., 2012) . It has been reported that the surfactant molecules stabilize the lipid core and might prevent particle agglomeration more efficiently (Rawat et al., 2011) . SLNs offer unique properties such as small size, large surface area, high drug loading and the interaction of phases at the interface and are attractive for their potential to improve performance of pharmaceuticals (Ekambaram et al., 2012; Mozafari, 2006) . Due to biodegradable and bioacceptable nature of SLN these are less toxic than polymeric nanoparticles and it also overcomes some disadvantages of traditional colloidal drug carrier system (Nikam et al., 2014) .
Dexamethasone (figure 1) is a synthetic adrenocortical steroid and is chemically designated as 9-fluoro-11β, 17, 21-trihydroxy-16α-methylpregna-1, 4-diene, 3, 20-dione. The drug is 25 times more potent than cortisol in its glucocorticoid effect, while having minimal mineralocorticoid effect. It has anti-inflammatory and immunosuppressant effects and is used for the treatment of many conditions including rheumatologic problems, a number of skin diseases such as erythema multiforme, severe allergies, asthma, chronic obstructive lung disease, croup, cerebral edema, in addition to other medications in tuberculosis and a number of other infectious diseases. However, it is characterized by a low water solubility (0.08 mg/ml at 25°C) and consequently low and irregular bioavailability (Swartz and Dluhy, 1978) . Also the therapeutic efficacy has been questioned with regard to its short half-life (O'Byrne and Pederson, 1998) , potential toxicity at high doses (Foster et al., 2006) . Therefore, some advanced delivery systems of drug need to be developed. Hence, in present experiment we, herein report about preparation of dexamethasone-loaded solid lipid nano particles with stearic as solid lipid and evaluation of enhanced dissolution rate as well as improved bioavailability.
INTRODUCTION MATERIALS AND METHODS

Materials
Dexamethasone was a gift sample from Square Pharmaceuticals Ltd, Dhaka, Bangladesh. Stearic acid was procured from Balami Fine Chemicals, India. Tween-80 and lutrol F-68 (Poloxamer) were received from BASF, Germany. All other reagents and solvent used were of analytical grade.
Methods
Preparation of dexamethasone SLNPs by hot homogenization method
The solid lipid nanoparticles of dexamethasone were prepared using the lipid (stearic acid); surfactant (lutrol F-68) and stabilizer (tween-80) at different proportion by hot homogenization technique (Mehnert and Mader, 2001; Kumar et al., 2012; Jahnke, 1998; Ahlim et al., 1998; Vyas and Khar, 2006) . At first dexamethasone was dissolved in acetone and the lipid was melted through hot plate by maintaining the temperature above the melting point 69.6°C of the lipid. The dissolved drug was mixed with melted lipid and heated until the evaporation of acetone occurs. Now surfactant and stabilizer were heated with distilled water on hot plate at the same temperature of lipid mixture. Hot surfactant solution was then added to the melted lipid-drug mixture and emulsified by a homogenizer (M-110P lab homogenizer, Trident Equipment's Pvt. Ltd., Mumbai, India) at 12000 rpm for 2 hours. The formulation was then removed from water bath and finally the dispersion of SLNPs was mixed gently at room temperature (table 1) .
In vitro dissolution study of dexamethasone solid lipid nanoparticles
In vitro dissolution studies of dexamethasone SLNPs were carried out to estimate the cumulative percentage of drug release with respect to time. 900ml distilled water containing 0.75% w/v SLS was placed in each vessel of the USP type II rotating paddle dissolution apparatus (Veego Vda 6DR, Germany). SLNPs were placed in each vessel and the medium was allowed to maintain at 50 rpm to a temperature of 37°±0.5°C for 50 minutes. 5 ml of the sample was withdrawn at definite time interval (10, 20, 30, 40 and 50 min) consecutively and replaced immediately by 5 ml of fresh media. The absorbance of sample was measured spectrophotometrically at λmax 239nm on a UVVisible spectrophotometer (UVmini-1240, Shimadzu Corp., Kyoto, Japan) and the values of dissolution efficiency were calculated (Khan and Rhodes, 1975) . 
Ct = C0 + K0t …. (1)
Where, K0 is the zero order rate constant expressed in units of concentration/time and t is the release time. A graph of concentration vs time would yield a straight line with a slope equal to K0 and intercept the origin of the axes (Hadjiioannou et al., 1993) 2.303 kt C Log C Log 0   Where, C0 is the initial concentration of drug, k is the first order rate constant and t is the time (Bourne, 2002) 
Where, Mt is the amount of drug release at time t, Mf is the amount of drug release after infinite time, t is the release time, K is the kinetic constant characteristic of the drug polymer/system and n is an exponent that characterizes the mechanism of release of drug (Korsmeyer et al., 1983) . A value of n = 0.45 indicates Fickian diffusion (case-I) release; 0.45 < n < 0.89 for non-Fickian diffusion (anomalous) release; n = 0.89 case-II transport and n > 0.89 indicates super case II release.
RESULTS AND DISCUSSION
The results of the dissolution studies are summarized in terms of percentage release of dexamethasone in 50 min period of time and also release kinetic modeling of drug from SLNPs. The drug release data were extrapolated by zero order, first order and Korsmeyer-Peppas equations as depicted by figure 2, 3 and 4. Regression coefficient (r 2 ) calculated from the slope of the plot and diffusion exponent 'n' are enlisted in table 2. For this system first order kinetic model yielded remarkably better linearity with r 2 0.931 to 0.987. Moreover, zero order and Korsmeyer-Peppas model yielded similarly good quality adjustments with r 2 0.883 to 0.998 and r 2 0.855 to 0.996 respectively. The analysis of experimental data in the light of the Korsmeyer-Peppas equation as well as interpretation of the corresponding release exponent 'n' leads to a better understanding of the release mechanism of drug. It is evident from the table 2 that 'n' values vary from 0.455 to 0.928 which is pointing to an anomalous (non-Fickian) diffusion mechanism. It may indicate that the drug release is controlled by more than one process that is a coupling of the diffusion and erosion mechanism. Researchers Fassihi and Ritschel also observed the similar results with a matrix tablet of theophylline with an 'n' value of 0.7 (Fassihi and Ritchel, 1993) . Formulated SLNPs exhibited significant improvement in the dissolution parameter of dexamethasone illustrated by figure 5. The order of dissolution enhancement with various SLNP systems was found to be DNP3>DNP2>DNP1>DNP6>DNP5>DNP4. As is evident from the Figure 5 the dissolution rate of DNP3 is higher (66.19%) and that of pure drug is lower (27.25%) even in 0.75% w/v SLS containing medium. Even when the percentage of drug release of this optimized formulation, DNP3 was compared with market preparation and pure drug (figure 6), optimized formulation showed highest release (66.19%) than market preparation (41.82%).
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The increase in dissolution rate is probably due to some factors, when lipid stearic acid is used to prepare SLNPs by homogenization method, this process converts the solid state of the drug from a crystalline material to an amorphous high energy state and dexamethasone is wetted more effectively by dissolution media with a greater dissolution rate. This lipid also increases the entrapment efficiency of dexamethasone by increasing the viscosity of medium which prevents rapid diffusion of drug into bulk of medium (Yang et al., 2000) . The high pressure homogenizer also helps to achieve a further reduction in particle size which is also credited to higher dissolution rate. During the in vitro dissolution assay, surfactants act in an important role to maintain the stability of SLNPs (Dong-Hwan and Martin, 2006) . When dexamethasone is released from SLNPs, the surfactant attaches to the hydrophobic nano particles surface and prevents the drug from diffusing back into the solid core of nano particles. Probably, all these factors could contribute together resulting in increased solubility and dissolution properties of dexamethasone solid lipid nano particles.
CONCLUSION
The therapeutic window of dexamethasone is narrow, so it is necessary to develop a SLNP system that releases the drug within this window. Thus, the formulation DNP3 with 1:1:1:2 ratio of drug, lipid, surfactant and stabilizer was considered better for this system, can be designed to improve dissolution rate and bioavailability of dexamethasone. 
